nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.06.2020 | Asthma (V Ortega, Section Editor)

Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations

verfasst von: Kenan Yalta, Tulin Yalta, Muhammet Gurdogan, Orkide Palabıyık, Ertan Yetkın

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The present paper aims to highlight clinical implications of elevated cardiac biomarkers and associated myocardial dysfunction in a variety of cardiac and non-cardiac scenarios in patients with an asthma exacerbation, and to propose a basic algorithm for cardiovascular evaluation and triage (and hence, for further management) of these patients primarily based on evaluation of cardiac biomarkers along with basic diagnostic modalities and specific cardiac symptoms in the hospital setting.

Recent Findings

Elevation of cardiac biomarkers in the setting of an asthma exacerbation mostly signifies a new-onset subclinical myocardial dysfunction/injury generally associated with certain asthma-related factors including acute hypoxemia and bronchodilator therapy, and usually has a limited prognostic value in these patients. On the other hand, elevation of these biomarkers in patients with an asthma exacerbation might also denote a variety of certain life-threatening cardiac or non-cardiac conditions associated with significant myocardial dysfunction (acute coronary syndromes (ACSs), sepsis, etc.) that might be masked by the rampant course of the asthma exacerbation, and hence, might possibly go undetected potentially aggravating the prognosis in a portion of these patients.

Summary

In patients with an asthma exacerbation, it seems imperative to timely diagnose and manage emerging diverse clinical conditions particularly through the guidance of cardiac biomarkers and associated myocardial dysfunction patterns in an effort to improve overall prognosis in these patients.

• Konstantinides SV, Torbicki A, Agnelli G, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC), et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69 3069a-3069k. Elaborates on elevation of cardiac biomarkers in certain life-threatening pulmonary conditions.PubMed

Yalta K, Sivri N, Yetkin E. Acute coronary syndromes in the setting of acute infections: is there an overdiagnosis with overtreatment? Int J Cardiol. 2011;149(3):383.PubMed

•• Shafuddin E, Chang CL, Cooray M, et al. Changes in biomarkers of cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Respir Med. 2018;145:192–9 Are important papers demonstrating potential value of cardiac enzymes in pulmonary obstructive diseases including acute bronchial asthma and associated conditions.PubMed

•• Jain M, Jain D, Das BK, et al. Original article: evaluation of cardiac biomarkers in children with acute severe bronchial asthma-a prospective study from tertiary care center in northern India. Indian Heart J. https://doi.org/10.1016/j.ihj.2018.10.416 (article in press). Are important papers demonstrating potential value of cardiac enzymes in pulmonary obstructive diseases including acute bronchial asthma and associated conditions.PubMedPubMedCentral

•• Kulkarni H, Akwei S, Luyt DK, et al. Cardiac troponin I levels in children with acute severe asthma treated with IV salbutamol. Lung Dis Treat. 2015;1:102. https://doi.org/10.4172/2472-1018.1000102Are important papers demonstrating potential value of cardiac enzymes in pulmonary obstructive diseases including acute bronchial asthma and associated conditions.

•• Kalyanaraman M, Bhalala U, Leoncio M. Serial cardiac troponin concentrations as marker of cardiac toxicity in children with status asthmaticus treated with intravenous terbutaline. Pediatr Emerg Care. 2011;27(10):933–6 Are important papers demonstrating potential value of cardiac enzymes in pulmonary obstructive diseases including acute bronchial asthma and associated conditions.PubMed

Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182–7.PubMed

Chang CL, Mills GD, Karalus NC, Jennings LC, Laing R, Murdoch DR, et al. Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults. PLoS One. 2013;8(5):e62612. https://doi.org/10.1371/journal.pone.0062612.PubMedPubMedCentral

Goritsas C, Fasoulaki M, Paissios NP, Giakoumaki E, Alamanos Y, Nikolaou NI. Brain natriuretic peptide plasma levels as a marker of prognosis in patients with community-acquired infection. Eur J Emerg Med. 2010;17(5):293–5.PubMed

10.

Moammar MQ, Ali MI, Mahmood NA, et al. Cardiac troponin I levels and alveolar-arterial oxygen gradient in patients with community-acquired pneumonia. Heart Lung Circ. 2010;19(2):90–2.PubMed

11.

•• Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–8 Are important papers demonstrating potential value of cardiac enzymes in pulmonary obstructive diseases including acute bronchial asthma and associated conditions.PubMed

12.

Cukic V, Lovre V, Dragisic D, Ustamujic A. Asthma and chronic obstructive pulmonary disease (COPD) - differences and similarities. Mater Sociomed. 2012;24(2):100–5.PubMedPubMedCentral

13.

•• Chaudary N, Geraci SA. Prognostic value of cardiac-specific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J Miss State Med Assoc. 2014;55(2):40–4 Are important papers demonstrating potential value of cardiac enzymes in pulmonary obstructive diseases including acute bronchial asthma and associated conditions.PubMed

14.

Hawkins NM, Khosla A, Virani SA, McMurray J, FitzGerald J. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med. 2017;17(1):11.PubMedPubMedCentral

15.

Roffi M, Patrono C, Collet JP, ESC Scientific Document Group, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.PubMed

16.

Rahman A, Broadley SA. Review article: elevated troponin: diagnostic gold or fool’s gold? Emerg Med Australas. 2014;26(2):125–30.PubMed

17.

Çavuşoğlu Y, Alper AT, Altay H, Çelik A, Demirkan B, Güvenç TS, et al. Natriuretic peptides in clinical practice. Anatol J Cardiol. 2019;21(Suppl 1):1–40.PubMed

18.

Calzetta L, Orlandi A, Page C, Rogliani P, Rinaldi B, Rosano G, et al. Brain natriuretic peptide: much more than a biomarker. Int J Cardiol. 2016;221:1031–8.PubMed

19.

•• Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–8. Suggests prognostic value of cardiac biomarkers in acute COPD exacerbations PubMed

20.

Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008;133(5):1088–94.PubMed

21.

•• RuDusky BM. Acute myocardial infarction and status asthmaticus: a case report. Angiology. 2006;57(5):655–8 Discusses acute cardiac conditions and overt myocardial complications in the course of acute bronchial asthma.PubMed

22.

Ahonen A. Analysis of the changes in ECG during status asthmaticus. Respiration. 1979;37:85–90.PubMed

23.

Siegler D. Reversible electrocardiographic changes in severe acute asthma. Thorax. 1977;32:328–32.PubMedPubMedCentral

24.

Yalta T, Yalta K. Systemic inflammation and arrhythmogenesis: a review of mechanistic and clinical perspectives. Angiology. 2018;69(4):288–96.PubMed

25.

Yalta K, Sivri N, Geyik B, et al. Sudden cardiac death due to β2-agonist therapy: is a genetic basis overlooked? Cardiovasc J Afr. 2012;23(2):97 102.PubMedPubMedCentral

26.

Kuroda R, Harada K, Kobayashi T, Nagai H, Unuma K, Saka K, et al. Sudden cardiac death caused by the administration of a β₂-agonist for asthma attack. Int J Cardiol. 2011;153(3):e56–8.PubMed

27.

Yalta K, Turgut OO, Yilmaz MB, et al. Genetic basis of sudden cardiac death due to emotional trauma in apparently healthy individuals. Int J Cardiol. 2010;145(3):518–9.PubMed

28.

Yalta K, Yilmaz A, Turgut OO, Yilmaz MB. Reduced repolarization reserve: an important but not the unique predictor of drug induced fatal ventricular arrhythmia. Int J Cardiol. 2008;124:368–9.

29.

Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax. 1995;50(10):1062–6.PubMedPubMedCentral

30.

Yalta K, Turgut O, Yilmaz A, Yilmaz MB, Kendirlioglu O, Karadas F. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake. Int J Cardiol. 2007;116(3):e95–7.PubMed

31.

• Ibanez B, James S, Agewall S, ESC Scientific Document Group, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77 Highlights value of cardiac enzymes in acute cardiac conditions.PubMed

32.

Miranda DF, Lobo AS, Walsh B, Sandoval Y, Smith SW. New insights into the use of the 12-lead electrocardiogram for diagnosing acute myocardial infarction in the emergency department. Can J Cardiol. 2018;34(2):132–45.PubMed

33.

Yalta K, Yilmaztepe M, Zorkun C. Left ventricular dysfunction in the setting of Takotsubo cardiomyopathy: a review of clinical patterns and practical implications. Card Fail Rev. 2018;4(1):14–20.PubMedPubMedCentral

34.

•• Kotsiou OS, Douras A, Makris D, et al. Takotsubo cardiomyopathy: a known unknown foe of asthma. J Asthma. 2017;54(8):880–6 Discusses acute cardiac conditions and overt myocardial complications in the course of acute bronchial asthma.PubMed

35.

Khwaja YH, Tai JM. Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation. BMJ Case Rep. 2016. https://doi.org/10.1136/bcr-2016-217364.

36.

Yalta K, Ucar F, Yilmaztepe M, Zorkun C. Takotsubo cardiomyopathy and acute coronary syndromes: are they always mutually exclusive? Indian Heart J. 2018;70(2):326–7.PubMed

37.

Yalta K, Ucar F, Yilmaztepe M, Ozkalayci F. Tako-tsubo cardiomyopathy and spontaneous coronary artery dissection: a subtle association with prognostic implications? Int J Cardiol. 2016;202:174–6.PubMed

38.

Koeth O, Zeymer U, Schiele R, Zahn R. Inferior ST-elevation myocardial infarction associated with Takotsubo cardiomyopathy. Case Rep Med. 2010. https://doi.org/10.1155/2010/467867.

39.

Yalta K, Yilmaztepe M, Ucar F, Takotsubo ZC. Cardiomyopathy? Acute myocarditis? Or both? Not so easy to diagnose in certain settings. Int J Cardiovasc Res. 6:3. https://doi.org/10.4172/2324-8602.1000310.

40.

Kawai S, Shimada T. Inflammation in takotsubo cardiomyopathy? Inquiry from “Guidelines for Diagnosis and Treatment of Myocarditis (JCS 2009)”. J Cardiol. 2014;63(4):247–9.PubMed

41.

Ruiz-Bailén M, Romero-Bermejo FJ, Rucabado-Aguilar L, Pérez-Valenzuela J, Ferrezuelo-Mata Á, Ramírez-Sánchez M, et al. Myocardial dysfunction in the critically ill patient: is it really reversible? Int J Cardiol. 2010;145(3):615–6.PubMed

42.

Yalta K, Yalta T, Sıvrı N, Aksoy Y, Yetkın E. Chronotropic incompetence: an obscure cause of heart failure symptoms in survivors of critical diseases? Int J Cardiol. 2011;147(1):171–2.PubMed

Titel: Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations
verfasst von: Kenan Yalta
Tulin Yalta
Muhammet Gurdogan
Orkide Palabıyık
Ertan Yetkın
Publikationsdatum: 01.06.2020
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 6/2020
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-020-00909-5

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO